ESTRO 2024 - Abstract Book

S2398

Clinical - Urology

ESTRO 2024

1.9% in the prostatic fossa. Pelvic nodal metastases were detected in 1 patient (1.0%), and pelvic bone metastases were found in another patient (1.0%). Among the 54 patients with positive mpMRI, 42 (75.0%) also underwent choline or PSMA-PET imaging. Among these 42 patients, 16 (38.1%) showed pathological tracer uptake in the same locations as the positive mpMRI. In the remaining 26 patients (61.9%), there was a discrepancy between the mpMRI findings and PET imaging results.

Conclusion:

The preliminary results revealed a higher-than-expected rate of macroscopic local recurrences in PCa patients with biochemical recurrence after radical prostatectomy. The findings challenge the current recommendations regarding the choice of imaging modalities for this patient population. This suggests that mpMRI may play a valuable role in assessing local recurrence and influencing treatment decisions in patients undergoing sRT following biochemical recurrence of PCa. Further research and analysis may be needed to confirm these findings and establish the most appropriate imaging strategies for these patients.

Keywords: mpMRI, salvage radiotherapy, local recurrence

1142

Digital Poster

Treatment-related parameters and acute toxicity in salvage radiotherapy of prostate cancer

Elena Natoli 1,2 , Maria Ntreta 3 , Letizia Cavallini 1,2 , Filippo Mammini 1,2 , Silvia Paolinelli 1,2 , Erika Galietta 1,2 , Viola Laghi 1,2 , Milly Buwenge 2 , Giorgio Coco 1,2 , Alessandra D'Alterio 1,2 , Pietro Del Pia 2 , Nadav Schindler 2 , Noam S. Darnell 2 , Arthur Sarmento Pinto Yanez 2 , Gabriella Macchia 4 , Francesco Deodato 4,5 , Selene Ciabatti 6 , Annalisa Cortesi 7 , Michele Benedetti 8 , Antonio Malorgio 9 , Ilaria Moschini 10 , Francesca Maurizi 11 , Alessandra Arcelli 1 , Alessio Giuseppe Morganti 1,2 1 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 2 Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University, Bologna, Italy. 3 Radiation Oncology, , IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. 4 Radiation Oncology, Gemelli Molise Hospital - Università Cattolica del Sacro Cuore, Campobasso, Italy. 5 Institute of Radiology, Università Cattolica del Sacro Cuore, Roma, Italy. 6 Radiotherapy Department, Ospedale Bellaria, Bologna, Italy. 7 IRCCS, Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy. 8 Radiotherapy Department, Ospedale Infermi, Rimini, Italy. 9 Department of Radiotherapy, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy. 10 Radiotherapy Department, Azienda Ospedaliera di Piacenza, Piacenza, Italy. 11 Radiation Oncology, A.O. Ospedali Riuniti Marche Nord, Pesaro, Italy

Purpose/Objective: